Clinical trials: Heart; Functional Disturbance
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart…
- Trial name
- NCT00748579
- Testing
- CK-1827452
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Cytokinetics
Heart Failure
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
This study will be conducted in subjects with clinical diagnosis of worsening chronic heart failure and either type 2 diabetes mellitus (DM) with or without chronic kidney disease (CKD) or moderate CKD alone treated with…
- Trial name
- ARTS-HF Japan (NCT01955694)
- Testing
- BAY94-8862, Eplerenone
- Where
- 29 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Bradycardia
Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response
This is a randomized, prospective, single-blinded, multi-center study involving approximately 1500 patients at 100 centers. The purpose of this study is to demonstrate the effectiveness of Closed Loop Stimulation (CLS) rate…
- Trial name
- CLEAR (NCT00355797)
- Testing
- Closed Loop Stimulation (CLS), Standard Rate Adaptive (R) Technology, Non-rate adaptive (DDD) pacing
- Where
- 99 sites in United States
- Volunteers
- 1,491 people
- Sponsor
- Biotronik, Inc.
Heart Failure, Ventricular Dysfunction
Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy
The WiCS-LV system is an alternative means to providing left ventricular stimulation for Cardiac Resynchronization Therapy (CRT).
- Conditions
- Heart Failure, Ventricular Dysfunction, Cardiomyopathy
- Trial name
- WiSE-CRT (NCT01294527)
- Testing
- Wireless cardiac stimulator implant to pace the left ventricle for CRT
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 17 people
- Sponsor
- EBR Systems, Inc.
Heart Failure, Congestive
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
- Trial name
- REMODEL (NCT00082589)
- Testing
- Eplerenone
- Where
- 53 sites in United States
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Left Ventricular Dysfunction
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.
- Trial name
- NCT00938847
- Testing
- PCI
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Asklepios proresearch
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics
Sick Sinus Syndrome, Heart Failure, Congestive
SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction
SAVE PACe is a large, prospective, single-blinded, randomized clinical trial with the main objective to study the effect of unnecessary right ventricular apical pacing on the clinical outcome of time to development of persistent…
- Conditions
- Sick Sinus Syndrome, Heart Failure, Congestive, Atrial Fibrillation, Bradycardia
- Trial name
- SAVEPACe (NCT00284830)
- Testing
- Implantable Pulse Generators
- Where
- 67 sites in United States, Canada
- Volunteers
- 1,070 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally
- Trial name
- ARTS (NCT01345656)
- Testing
- BAY94-8862, Spironolactone
- Where
- 50 sites in Austria, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Bayer
Heart Failure, Congestive, Ventricular Dysfunction
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
The purpose of this study is to determine the safety and effectiveness of the Thoratec HeartMate II Left Ventricular Assist System (LVAS) as Destination Therapy in end-stage heart failure patients who do not qualify for cardiac…
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Trial name
- NCT00121485
- Testing
- Left Ventricular Assist System (LVAS)
- Where
- 47 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Cognitive Impairment
HeartMapp: Assessment and Treatment for Heart Failure
In the current application, the investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and…
- Trial name
- HeartMapp (NCT03827954)
- Testing
- HeartMapp+CT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Posit Science Corporation
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.
RV - Right Ventricular Abnormality, LV Dysfunction
Pediatric Ventricle Function Assessment Study
This study aims to develop a deep learning-based framework for right ventricular (RV) segmentation, prediction of RV fractional area change (FAC), and identification of pediatric RV dysfunction.
- Conditions
- RV - Right Ventricular Abnormality, LV Dysfunction, Pulmonary Hypertension, TOF
- Trial name
- NCT06739057
- Where
- United States
- Volunteers
- 3,993 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in…
- Trial name
- CALLIPER (NCT03359876)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin sodium
- Where
- United States
- Volunteers
- 16,000 people
- Sponsor
- Bayer
Congestive Heart Failure, Left Bundle Branch Block
MADIT ASIA Cardiac Resynchronization Trial
The purpose of this trial or study is to determine if pacemaker therapy can be a beneficial alternative to conventional medical therapy in patients with a history of moderate heart failure.
- Conditions
- Congestive Heart Failure, Left Bundle Branch Block, Heart Failure, Systolic
- Trial name
- MADIT-ASIA (NCT01872234)
- Testing
- Two-lead CRT-P
- Where
- 21 sites in China, India and 6 more
- Volunteers
- 1 people
- Sponsor
- Boston Scientific Corporation
Psychological Stress, Anxiety
NeuroFinance Human Stress Trial During Financial and Informational Volatility
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven…
- Conditions
- Psychological Stress, Anxiety, Emotional Stress, Autonomic Nervous System Dysfunction
- Trial name
- NFHST (NCT07622589)
- Testing
- Wearable Physiologic Monitoring Platform
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Acute Myocardial Infarction
Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI
Development of myocardial reparative therapy for the treatment of acute ischemic cardiac disease, based on the intracoronary administration of allogeneic Cardiac Stem Cells (CSCs) to ameliorate myocardial cell death and promote…
- Trial name
- CAREMI (NCT02439398)
- Testing
- Allogeneic human cardiac stem cells (CSCs), Human Serum Albumin-HSA 5%
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Coretherapix
Tachycardia, Ventricular, Heart Failure, Congestive
OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.
The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life…
- Conditions
- Tachycardia, Ventricular, Heart Failure, Congestive, Ventricular Fibrillation, Ventricular Dysfunction
- Trial name
- OMNI (NCT00277524)
- Where
- 113 sites in United States
- Volunteers
- 3,032 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure